retatrutide trial VisualAbstract: reduces body weight by 17.5% in patients with obesity The numbers from Lilly's Phase

Visit Doctronic.ai and create an account

GLP-1 medications have changed obesity medicine

Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors, distinguishing it from currently approved weight management agents

These statements have not been evaluated by the Food and Drug Administration

Despite this, there is a growing and concerning market for retatrutide and other research peptides sold online, often marketed to bodybuilders or individuals seeking weight loss

It was the medicine my body needed, she explains, noting that traditional approaches simply werent enough anymore